Concepts (68)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vicia faba | 1 | 2012 | 1 | 0.440 |
Why?
|
| Microcystis | 1 | 2012 | 1 | 0.440 |
Why?
|
| Microcystins | 1 | 2012 | 2 | 0.440 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2013 | 91 | 0.430 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2012 | 34 | 0.430 |
Why?
|
| Cell Membrane | 2 | 2013 | 850 | 0.390 |
Why?
|
| Microtubules | 1 | 2012 | 270 | 0.390 |
Why?
|
| Databases, Factual | 1 | 2018 | 2218 | 0.390 |
Why?
|
| Depsipeptides | 1 | 2011 | 78 | 0.380 |
Why?
|
| Precision Medicine | 1 | 2018 | 1154 | 0.370 |
Why?
|
| Medical Oncology | 1 | 2018 | 1423 | 0.350 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2011 | 661 | 0.290 |
Why?
|
| Chromatin | 1 | 2012 | 942 | 0.290 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 1555 | 0.280 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2016 | 1763 | 0.280 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2011 | 1146 | 0.260 |
Why?
|
| ErbB Receptors | 1 | 2013 | 2295 | 0.240 |
Why?
|
| Immunotherapy | 1 | 2016 | 3341 | 0.220 |
Why?
|
| Receptor, ErbB-2 | 1 | 2013 | 2518 | 0.220 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 3251 | 0.200 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 4654 | 0.180 |
Why?
|
| Melanoma | 1 | 2016 | 5317 | 0.170 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 7789 | 0.160 |
Why?
|
| Mutation | 1 | 2016 | 15179 | 0.140 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 11538 | 0.120 |
Why?
|
| Photobleaching | 1 | 2013 | 5 | 0.110 |
Why?
|
| Image Cytometry | 1 | 2013 | 47 | 0.110 |
Why?
|
| Meristem | 1 | 2012 | 3 | 0.110 |
Why?
|
| Marine Toxins | 1 | 2012 | 12 | 0.110 |
Why?
|
| CTLA-4 Antigen | 1 | 2016 | 657 | 0.110 |
Why?
|
| Time-Lapse Imaging | 1 | 2011 | 18 | 0.100 |
Why?
|
| Ipilimumab | 1 | 2016 | 710 | 0.100 |
Why?
|
| Plant Proteins | 1 | 2012 | 133 | 0.100 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2013 | 280 | 0.100 |
Why?
|
| T-Lymphocytes | 2 | 2016 | 3869 | 0.100 |
Why?
|
| Protein Structure, Quaternary | 1 | 2011 | 138 | 0.100 |
Why?
|
| Intracellular Space | 1 | 2011 | 77 | 0.100 |
Why?
|
| Cricetulus | 1 | 2011 | 205 | 0.100 |
Why?
|
| Exome | 1 | 2016 | 1239 | 0.100 |
Why?
|
| CHO Cells | 1 | 2011 | 311 | 0.100 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2012 | 214 | 0.100 |
Why?
|
| GPI-Linked Proteins | 1 | 2011 | 223 | 0.090 |
Why?
|
| Tumor Burden | 1 | 2016 | 1987 | 0.090 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 663 | 0.090 |
Why?
|
| Protein Multimerization | 1 | 2011 | 240 | 0.090 |
Why?
|
| Cricetinae | 1 | 2011 | 706 | 0.090 |
Why?
|
| Drug Discovery | 1 | 2013 | 324 | 0.090 |
Why?
|
| Mitosis | 1 | 2012 | 615 | 0.090 |
Why?
|
| Protein Transport | 1 | 2011 | 734 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 14289 | 0.080 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2011 | 703 | 0.080 |
Why?
|
| Antibodies | 1 | 2011 | 838 | 0.080 |
Why?
|
| Cell Line, Tumor | 2 | 2013 | 14551 | 0.070 |
Why?
|
| Cell Cycle | 1 | 2012 | 2084 | 0.070 |
Why?
|
| Algorithms | 1 | 2016 | 3890 | 0.060 |
Why?
|
| Histones | 1 | 2012 | 1466 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 1879 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2012 | 4804 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 4938 | 0.060 |
Why?
|
| Cell Movement | 1 | 2011 | 2466 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2016 | 9244 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 4367 | 0.060 |
Why?
|
| Humans | 5 | 2018 | 261506 | 0.050 |
Why?
|
| Animals | 2 | 2011 | 59536 | 0.040 |
Why?
|
| Female | 2 | 2016 | 141928 | 0.030 |
Why?
|
| Middle Aged | 1 | 2016 | 86204 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 15694 | 0.020 |
Why?
|
| Male | 1 | 2016 | 123000 | 0.020 |
Why?
|